A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma
Abstract Background Approximately 50% of uveal melanoma (UM) patients develop metastases preferentially in the liver leading to death within 15 months. Currently, there is no effective treatment for metastatic UM, in part because the tumor burden is typically high when liver metastases are detected...
Main Authors: | Jin Song, Shannath L. Merbs, Lori J. Sokoll, Daniel W. Chan, Zhen Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Clinical Proteomics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12014-019-9230-8 |
Similar Items
-
Blood Biomarkers of Uveal Melanoma: Current Perspectives
by: Bande Rodríguez MF, et al.
Published: (2020-01-01) -
Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma
by: Daniel A. Rodriguez, et al.
Published: (2020-10-01) -
INCREASED LEVELS OF MIRNA-146A IN SERUM AND HISTOLOGIC SAMPLES OF PATIENTS WITH UVEAL MELANOMA
by: ANDREA RUSSO, et al.
Published: (2016-11-01) -
The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression
by: Joanna Patrycja Wróblewska, et al.
Published: (2021-07-01) -
Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk
by: Gabriel Velez, et al.
Published: (2021-02-01)